

Product Information



CD150 Monoclonal Antibody (Clone IPO-3)

Item No. 10004804

Contents:	This vial contains 100 µg of affinity-purified IgG ₁ in 100 µl PBS, pH 7.2
Synonyms:	CDw150, IPO-3, SLAM
Host:	Mouse, clone IPO-3
Cross Reactivity:	(+) Human CD150; other species not tested.
Stability:	≥1 year at 4°C
Applications:	Flow cytometry, immunocytochemistry, immunohistochemistry (frozen sections), and immunoprecipitation; the recommended starting dilution for these applications is 1-10 µg/ml. A dilution of 10 µg/ml is recommended for receptor ligation experiments. ^{1,2}

Revealing the molecular signals involved in B and T cell activation is critical to the future discovery of therapeutics that can augment cell-mediated immune responses to disease.¹⁻³ CD150 is a type I transmembrane glycoprotein that is involved in signal transduction of antigen specific responses in B and T cells. It is expressed by activated B cells isolated from tonsils and peripheral blood, B cells in germinal centers and mantle zone of lymph nodes, immature thymocytes, and CD45RO⁺CD45RA⁻ subpopulation of T cells.^{4,5} This antibody has been used to detect CD150 in neoplastic cells from diffuse large B-cell lymphoma, Hodgkin's disease, hairy cell leukemia, and some tumors of ectodermal origin.⁶

References

1. Mikhalap, S.V., Shlapatska, L.M., Yurchenko, O.V., *et al.* The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells. *Blood* **104**(13), 4063-4070 (2004).
2. Mikhalap, S.V., Shlapatska, L.M., Berdova, A.G., *et al.* CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. *J. Immunol.* **162**, 5719-5727 (1999).
3. Shlapatska, L.M., Mikhalap, S.V., Berdova, A.G., *et al.* CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. *J. Immunol.* **166**, 5480-5487 (2001).
4. Cocks, B.G., Chang, C.-C.J., Carballido, J.M., *et al.* A novel receptor involved in T-cell activation. *Nature* **376**, 260-263 (1995).
5. Sidorenko, S.P. and Clark, E.A. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. *J. Immunol.* **151**, 4614-4624 (1993).
6. Pinchouk, V.G., Sidorenko, S.P., Gluzman, D.F., *et al.* Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens. *Anticancer Res.* **8**, 1377-1380 (1988).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/10004804

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery**.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 01/10/2014

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com